Maxim Group analyst Jason McCarthy maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report) yesterday and set a price target of $10.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Jason McCarthy has given his Buy rating due to a combination of factors including Lipella Pharmaceuticals, Inc.’s recent positive results from its Phase 2a study of LP-310, targeting oral lichen planus (OLP). The study demonstrated significant efficacy improvements across key symptoms such as pain, ulceration, and inflammation, and showed a strong safety profile with no serious adverse events reported.
The progression of the study to a higher dose cohort signifies potential for further positive outcomes, with plans to submit for a Phase 2b study and potentially request Breakthrough Therapy designation from the FDA in the second half of 2025. These developments suggest promising prospects for LP-310, contributing to McCarthy’s optimistic outlook and Buy rating for Lipella’s stock.
McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Lipella Pharmaceuticals, Inc., and Alterity Therapeutics. According to TipRanks, McCarthy has an average return of -14.9% and a 28.83% success rate on recommended stocks.